Simulect (Basiliximab)

Simulect is manufactured in Germany and shipped by courier from our pharmacy in India.

Information about Simulect (Basiliximab)

Simulect, also known by its generic name basiliximab, is a monoclonal antibody medication used primarily in the prevention of acute rejection in organ transplantation, particularly kidney transplants. It works by targeting and blocking the interleukin-2 (IL-2) receptor, which plays a key role in the activation and proliferation of T-cells that mediate rejection. This medication is typically used in combination with other immunosuppressive therapies to prevent organ rejection.

Product Highlights

• Prevention of early organ rejection in patients undergoing kidney transplantation. 
• It is used in conjunction with other immunosuppressive agents to prevent rejection following the transplantation of a kidney.

Key Ingredient

• Basiliximab

Key Benefits

• By inhibiting T-cell activation, Simulect helps to prevent the body from attacking the newly transplanted kidney.
• It helps to reduce reliance on steroids, which can have significant side effects when used long-term.
• With appropriate use alongside other immunosuppressive drugs, basiliximab improves the chances of transplant success and reduces the risk of transplant failure.
• Basiliximab is associated with a lower incidence of adverse effects such as infection and malignancies compared to other immunosuppressive therapies.

Direction of Use

• Simulect is administered through an intravenous infusion.
• A typical regimen involves a 2-dose schedule:
• First dose is given within 2 hours prior to transplant.
• Second dose is administered 4 days after the first dose.
• The healthcare provider will monitor the patient for side effects during and after the infusion.

Safety Concerns

• Since Simulect suppresses the immune system, there is an increased risk of infections, including viral, bacterial, and fungal infections.
• Though rare, an allergic reaction or anaphylaxis may occur during or shortly after infusion.
• Basiliximab may contribute to high blood pressure in some individuals.
• While Simulect reduces the risk of acute rejection, it does not eliminate the possibility, and careful monitoring is necessary.
• Long-term use of immunosuppressive medications, including basiliximab, may increase the risk of certain cancers, such as lymphoma and skin cancers.

Avoid Simulect (Basiliximab) If

• If you have a known allergy to basiliximab or any other components in the formulation, Simulect should be avoided.
• Basiliximab should not be used in patients with active infections, as it could exacerbate the condition due to its immunosuppressive effects.
• Individuals with severe immune system dysfunction may have an increased risk of complications with Simulect use.
• Simulect should be used carefully during pregnancy and breastfeeding. It is advised to avoid it unless the potential benefit outweighs the risks, as there are limited studies on its safety during these periods.